Nan J - Search Results

1

Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387.

Wang Y, Nan J, Willard B, Wang X, Yang J, Stark GR. Wang Y, et al. Among authors: nan j. EMBO J. 2017 Jan 17;36(2):202-212. doi: 10.15252/embj.201694834. Epub 2016 Nov 16. EMBO J. 2017. PMID: 27852626 Free PMC article.

2

IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression.

Nan J, Wang Y, Yang J, Stark GR. Nan J, et al. Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3906-3911. doi: 10.1073/pnas.1714102115. Epub 2018 Mar 26. Proc Natl Acad Sci U S A. 2018. PMID: 29581268 Free PMC article.

3

A virus-induced conformational switch of STAT1-STAT2 dimers boosts antiviral defenses.

Wang Y, Song Q, Huang W, Lin Y, Wang X, Wang C, Willard B, Zhao C, Nan J, Holvey-Bates E, Wang Z, Taylor D, Yang J, Stark GR. Wang Y, et al. Among authors: nan j. Cell Res. 2021 Feb;31(2):206-218. doi: 10.1038/s41422-020-0386-6. Epub 2020 Aug 5. Cell Res. 2021. PMID: 32759968 Free PMC article.

4

Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.

Chen X, Du Y, Nan J, Zhang X, Qin X, Wang Y, Hou J, Wang Q, Yang J. Chen X, et al. Among authors: nan j. PLoS One. 2013 May 21;8(5):e63697. doi: 10.1371/journal.pone.0063697. Print 2013. PLoS One. 2013. PMID: 23704931 Free PMC article.

5

Loss of ZIP facilitates JAK2-STAT3 activation in tamoxifen-resistant breast cancer.

Zhu N, Zhang J, Du Y, Qin X, Miao R, Nan J, Chen X, Sun J, Zhao R, Zhang X, Shi L, Li X, Lin Y, Wei W, Mao A, Zhang Z, Stark GR, Wang Y, Yang J. Zhu N, et al. Among authors: nan j. Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15047-15054. doi: 10.1073/pnas.1910278117. Epub 2020 Jun 12. Proc Natl Acad Sci U S A. 2020. PMID: 32532922 Free PMC article.

6

TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.

Nan J, Du Y, Chen X, Bai Q, Wang Y, Zhang X, Zhu N, Zhang J, Hou J, Wang Q, Yang J. Nan J, et al. Mol Cancer Ther. 2014 Mar;13(3):617-29. doi: 10.1158/1535-7163.MCT-13-0464. Epub 2014 Jan 8. Mol Cancer Ther. 2014. PMID: 24401319

7

Dehydrocrenatidine is a novel janus kinase inhibitor.

Zhang J, Zhu N, Du Y, Bai Q, Chen X, Nan J, Qin X, Zhang X, Hou J, Wang Q, Yang J. Zhang J, et al. Among authors: nan j. Mol Pharmacol. 2015 Apr;87(4):572-81. doi: 10.1124/mol.114.095208. Epub 2015 Jan 12. Mol Pharmacol. 2015. PMID: 25583084

8

Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.

Sun J, Du Y, Zhang X, Wang Z, Lin Y, Song Q, Wang X, Guo J, Li S, Nan J, Yang J. Sun J, et al. Among authors: nan j. Invest New Drugs. 2020 Aug;38(4):1003-1011. doi: 10.1007/s10637-019-00853-w. Epub 2019 Oct 14. Invest New Drugs. 2020. PMID: 31612426

9

E2F is required for STAT3-mediated upregulation of cyclin B1 and Cdc2 expressions and contributes to G2-M phase transition.

Sun J, Du Y, Song Q, Nan J, Guan P, Guo J, Wang X, Yang J, Zhao C. Sun J, et al. Among authors: nan j. Acta Biochim Biophys Sin (Shanghai). 2019 Mar 1;51(3):313-322. doi: 10.1093/abbs/gmy174. Acta Biochim Biophys Sin (Shanghai). 2019. PMID: 30726872 Free article.

10

TGF-β2 antagonizes IL-6-promoted cell survival.

Du Y, Sun J, Liu X, Nan J, Qin X, Wang X, Guo J, Zhao C, Yang J. Du Y, et al. Among authors: nan j. Mol Cell Biochem. 2019 Nov;461(1-2):119-126. doi: 10.1007/s11010-019-03595-8. Epub 2019 Jul 29. Mol Cell Biochem. 2019. PMID: 31359244

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

745 results

Search Page

Filters